MLV & Co Upgrades Acura Pharmaceuticals To Buy
Analysts MLV & Co upgraded Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) from Hold to Buy.
The price target for Acura Pharmaceuticals is set to $1.
Acura Pharmaceuticals shares have dropped 61.62% over the past 52 weeks, while the S&P 500 index has surged 13.51% in the same period.
Acura Pharmaceuticals' shares rose 6.76% to $0.79 in after-hours trading.
Latest Ratings for ACUR
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 2016 | Roth Capital | Initiates Coverage On | Buy | |
| Feb 2015 | MLV & Co. | Upgrades | Hold | Buy |
| May 2014 | MLV & Co. | Downgrades | Buy | Hold |
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: MLV & CoUpgrades Analyst Ratings
